The aim of this multi-institutional study was to identify predictors of residual high-grade (HG) disease at re-transurethral resection (reTUR) in a large cohort of primary T1 HG/Grade 3 (G3) bladder cancer patients. A total of 1155 patients with primary T1 HG/G3 bladder cancer from 13 academic institutions that underwent a reTUR within 6 weeks after first TUR were evaluated. Logistic regression analysis was performed to assess the association of predictive factors with residual HG at reTUR. Residual HG cancer was found in 288 (24.9%) of patients at reTUR. Patients presenting residual HG cancer were more likely to have carcinoma in situ (CIS) at first resection (p<0.001), multiple tumors (p=0.02), and tumor size larger than 3 cm (p=0.02). Residual HG disease at reTUR was associated with increased preoperative neutrophil-to-lymphocytes ratio (NLR) (p=0.006) and body mass index (BMI)>=25 kg/m2. On multivariable analysis, independent predictors for HG residual disease at reTUR were tumor size >3cm (OR = 1.37; 95% CI: 1.02-1.84, p=0.03), concomitant CIS (OR 1.92; 95% CI: 1.32-2.78, p=0.001), being overweight (OR= 2.08; 95% CI: 1.44-3.01, p<0.001) and obesity (OR 2.48; 95% CI: 1.64-3.77, p<0.001). A reTUR in high grade T1 bladder cancer is mandatory as about 25% of patients, presents residual high grade disease. Independent predictors to identify patients at risk of residual high grade disease after a complete TUR include tumor size, presence of carcinoma in situ, and BMI >=25 kg/m2.
Journal of Cancer. 2018 Oct 20*** epublish ***
Matteo Ferro, Giuseppe Di Lorenzo, Carlo Buonerba, Giuseppe Lucarelli, Giorgio Ivan Russo, Francesco Cantiello, Abdal Rahman Abu Farhan, Savino Di Stasi, Gennaro Musi, Rodolfo Hurle, Serretta Vincenzo, Gian Maria Busetto, Ettore De Berardinis, Sisto Perdonà, Marco Borghesi, Riccardo Schiavina, Gilberto L Almeida, Pierluigi Bove, Estevao Lima, Giovanni Grimaldi, Deliu Victor Matei, Francesco Alessandro Mistretta, Nicolae Crisan, Daniela Terracciano, Verze Paolo, Michele Battaglia, Giorgio Guazzoni, Riccardo Autorino, Giuseppe Morgia, Rocco Damiano, Matteo Muto, Roberto La Rocca, Vincenzo Mirone, Ottavio de Cobelli, Mihai Dorin Vartolomei
Division of Urology, European Institute of Oncology, Milan, Italy., Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy., Department of Emergency and Organ Transplantation, Urology, Andrology and Kidney Transplantation Unit, University of Bari, Bari, Italy., Department of Urology, University of Catania, Catania, Italy., Department of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy., Urology Unit, Policlinico Tor Vergata, University of Rome, Rome, Italy., Department of Urology, Istituto Clinico Humanitas, Clinical and Research Hospital, Milan, Italy., Division of Urology, University of Palermo, Palermo, Italy., Department of Urology, La Sapienza University of Rome, Rome, Italy., Department of Uro-Gynaecological Oncology, Istituto Nazionale Tumori "Fondazione G. Pascale", IRCCS, Naples, Italy., Department of Urology, University of Bologna, Bologna, Italy., Department of Urology, University of Vale do Itajaí, Itajaí, Brazil., Department of Experimental Medicine and Surgery, Urology Unit, Azienda Policlinico Tor Vergata, Rome, Italy., Department of CUF Urology and Life and Health Sciences Research Institute, School of Medicine, University of Minho, Portugal., Department of Urology, University of Medicine and Pharmacy "Iuliu Hațieganu", Cluj-Napoca, Romania., Department of Translational Medical Sciences, University of Naples "Federico II", Naples, Italy., Department of Neurosciences, Sciences of Reproduction and Odontostomatology, Urology Unit, University of Naples "Federico II", Naples, Italy., Division of Urology, Virginia Commonwealth University, Richmond, VA, USA., Istituto Zooprofilattico Sperimentale del Mezzogiorno, Portici, Italy., Department of Clinical Medicine and Surgery, Federico II University Medical School of Naples, Italy.